Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer

Citation
C. Erlichman et al., Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer, J CL ONCOL, 17(5), 1999, pp. 1356-1363
Citations number
31
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
JOURNAL OF CLINICAL ONCOLOGY
ISSN journal
0732-183X → ACNP
Volume
17
Issue
5
Year of publication
1999
Pages
1356 - 1363
Database
ISI
SICI code
0732-183X(199905)17:5<1356:EOAFAF>2.0.ZU;2-C
Abstract
Purpose: The goal of this analysis was to determine whether fluorouracil (F U) and folinic acid (leucovorin, LV) is an effective adjuvant therapy for p atients after potentially curative resection of colon cancer in patients wi th B2 tumors. Patients and Methods: One thousand sixteen patients with B2 colon cancer en tered onto five separate trials were randomized to FU + LV or observation, A pooled analysis for event-free (EFS) and overall survival (OS) using a st ratified lag-rank and Cox model was performed. Results: The median follow-vp duration was 5.75 years. Patients receiving F U + LV did not experience a significant increase in EFS or OS. The hazards ratio at 5 years was 0.83 (90% confidence interval, 0.72 to 1.07) for EFS a nd 0.86 (90% confidence interval, 0.68 to 1.07) for OS. The 5-year EFS was 73% for controls and 76% for FU + LV.The 5-year OS war 80% for controls and 82% for FU + LV. Increasing age and pearly differentiated tumors were sign ificant indicators of poor prognosis (P <.02). Conclusion: This data set does not support the routine use of + LV in all p atients with B2 colon cancer. ranger follow-up may identify a small benefit . At present, studies in B2 colon cancer designed with a no-treatment contr ol arm should be considered appropriate. J Clin Oncol 17:1356-1363. (C) 199 9 by American Society of Clinical Oncology.